GlassScriptPhysician profile
Anthony Iannamorelli
NPI 1194778266
$4,208.50
in general payments reported to CMS, 2019-2025
38 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $306 · 2022: $16.09 · 2023: $244 · 2024: $1,335 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $906.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $482.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $354.79 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $266.57 | 2019-2024 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Astellas Pharma US INC | $186.22 | 2019-2025 | Veozah |
| Abbvie INC. | $148.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $138.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $134.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Scilex Pharmaceuticals INC. | $133.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.39 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.65 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Amgen INC. | $116.94 | 2019-2025 | Krystexxa, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $107.59 | 2019-2024 | Camzyos |
| Amarin Pharma, INC. | $99.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.78 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.91 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $63.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.33 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $56.20 | 2019 | |
| Sanofi Pasteur INC. | $50.44 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $42.85 | 2023-2024 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $38.43 | 2019 | |
| Tactile Systems Technology INC | $37.45 | 2024 | Entre Plus, Flexitouch Plus |
| Phathom Pharmaceuticals, INC. | $36.83 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $36.08 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $35.64 | 2019 | |
| Gilead Sciences, INC. | $35.28 | 2019 | |
| Exact Sciences Corporation | $33.59 | 2025 | Cologuard Collection Kit |
| Seqirus USA INC | $31.81 | 2025 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $24.08 | 2023 | Quviviq |
| Genentech USA, INC. | $21.84 | 2019 | |
| Esperion Therapeutics, INC. | $20.28 | 2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $19.51 | 2024 | Unithroid |
| Verona Pharma, INC. | $18.70 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $18.35 | 2025 | Zenpep |
| Hikma Pharmaceuticals USA | $16.09 | 2019 | |
| Pulmonx Corporation | $15.82 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Allergan, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Iannamorelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.